A Phase 1 Study to Investigate the Effects of Cortexolone 17α-Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity

    May 2021 in “ Clinical Pharmacology in Drug Development ”
    Jörg Täubel, Alessandro Mazzetti, Georg Ferber … John Camm
    Studysummary This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 5

    1. Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris American Journal of Clinical Dermatology · 2019
    2. Penetration Enhancement of Topical Formulations Pharmaceutics · 2018
    3. The Role of Hair Follicles in the Percutaneous Absorption of Caffeine BJCP. British journal of clinical pharmacology/British journal of clinical pharmacology · 2007
    4. New Topical Antiandrogenic Formulations Can Stimulate Hair Growth in Human Bald Scalp Grafted Onto Mice International Journal of Pharmaceutics · 2000
    5. Local and Systemic Reduction by Topical Finasteride or Flutamide of Hamster Flank Organ Size and Enzyme Activity Journal of Investigative Dermatology · 1995